ImageneBio Appoints Matt Robbins as General Counsel
ImageneBio appointed Matt Robbins as General Counsel effective July 7, 2026, bringing over 15 years of corporate and securities law experience to the management team. Robbins, previously General Counsel at Bright Peak Therapeutics and an attorney at Cooley LLP, will oversee legal and compliance functions as the company advances its lead candidate.
Key figures
- Drug Name
- IMG-007
- Phase Of Trial
- Phase 2b
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.